Skip to content
Triangle logo TriangleGet started
← Study library

NCT00025233 · CITED IN SOURCE DOCUMENTS

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-07-24

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival Greater Than 6 Months

→

outcome · POSTED

Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0

→

outcome · POSTED

Tumor Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Duration of Progression-free Survival

→

outcome · POSTED

Performance Status

→

outcome · POSTED

Age at Enrollment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed persistent or recurrent squamous cell carcinoma (SCC) of the cervix * Patients must have received at least 1, but no more than 2, prior cytotoxic chemotherapy regimens for advanced, metastatic, or recurrent SCC of the cervix * Chemotherapy administered as a radio-sensitizer does not count as 1 regimen * Documented disease progression * At least 1 unidimensionally measurable lesion\* * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan * No tumor involving major blood vessels * No history or physical evidence of CNS disease, including primary or metastatic brain tumor * Ineligible for a higher priority Gynecological Oncology Group (GOG) protocol (if one exists), including any active GOG phase III protocol for the same patient population * Performance status - GOG 0-2 (if received 1 prior regimen) * Performance status - GOG 0-1 (if received 2 prior regimens) * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No known bleeding disorder or coagulopathy * No other active bleeding or pathologic condition that would confer a high risk of bleeding * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * SGOT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * INR ≤ 1.5 (or 2-3 for patients on a stable dose of therapeutic warfarin or low molecular weight heparin) * PTT \< 1.2 times control * Creatinine ≤ 1.5 times ULN * Creatinine clearance \> 60 mL/min * No proteinuria * Urine protein \< 1+ on dipstick or \< 30 mg/dL * Urine protein \< 1000 mg by 24-hour urine collection * No clinically significant cardiovascular disease * No uncontrolled hypertension * No myocardial infarction or unstable angina within the past 6 months * No New York Heart Association grade II-IV congestive heart failure * No serious cardiac arrhythmia requiring medication * No grade II or greater peripheral vascular disease * No history of stroke within the past 5 years * No greater than grade 1 sensory or motor neuropathy * No active infection requiring parenteral antibiotics * No serious nonhealing wound, ulcer, or bone fracture * No history or physical evidence of seizures not controlled with standard medical therapy * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No other invasive malignancy within the past 5 years except nonmelanomatous skin cancer * No significant traumatic injury within the past 4 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment * No prior bevacizumab * At least 3 weeks since prior immunologic agents for SCC of the cervix * See Disease Characteristics * Recovered from prior chemotherapy * No prior non-cytotoxic chemotherapy for persistent or recurrent disease * At least 1 week since prior hormonal therapy for SCC of the cervix * Concurrent hormone replacement therapy allowed * See Disease Characteristics * Recovered from prior radiotherapy * Recovered from recent prior surgery * At least 4 weeks since prior major surgical procedure or open biopsy * At least 1 week since prior placement of vascular access device or core biopsy * No concurrent major surgical procedure * At least 3 weeks since other prior therapy for SCC of the cervix * No prior anticancer therapy that would preclude study therapy * No concurrent anticoagulants other than those required to maintain the patency of indwelling IV catheters * No concurrent chronic daily aspirin greater than 325 mg/day or other nonsteroidal anti-inflammatory medications that are known to inhibit platelet function at doses used for chronic inflammatory diseases
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: bevacizumab
    2. Other: laboratory biomarker analysis
    label
    Treatment (bevacizumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (bevacizumab)
    description
    Given IV
    name
    bevacizumab
    other Names
    1. anti-VEGF humanized monoclonal antibody
    2. anti-VEGF monoclonal antibody
    3. Avastin
    4. rhuMAb VEGF
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (bevacizumab)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
50
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Whether or not the patient survived progression-free for at least 6 months.
    measure
    Progression-free Survival Greater Than 6 Months
    time Frame
    Every other 3-week treatment cycle for 6 months
  2. description
    The maximum severity of each adverse event per patient, graded according to Common Toxicity Criteria version 2.0, is reported. Events were restricted to those reported as at least possibly related to study drug.
    measure
    Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0
    time Frame
    Every cycle and 30 days after the end of treatment. (average 5 months)
secondary Outcomes
  1. description
    RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate.
    measure
    Tumor Response
    time Frame
    Every other cycle during treatment and at the time of treatment discontinuation. (average 5 months)
  2. description
    The observed length of life from entry into the study to death or the date of last contact.
    measure
    Overall Survival
    time Frame
    From study entry to death or last contact, up to 5 years.
  3. description
    Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.
    measure
    Duration of Progression-free Survival
    time Frame
    Every other cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years
  4. description
    Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
    measure
    Performance Status
    time Frame
    Baseline
  5. measure
    Age at Enrollment
    time Frame
    Baseline
Full study description
brief Summary
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
detailed Description
OBJECTIVES: I. Determine the cytostatic antitumor activity of bevacizumab, in terms of 6-month progression-free survival (PFS), in patients with persistent or recurrent squamous cell carcinoma of the cervix. II. Determine the nature and degree of toxicity of this drug in these patients. III. Estimate the distribution of PFS and overall survival for patients treated with this drug. IV. Determine the frequency of clinical response (partial and complete) in patients treated with this drug. V. Determine the role of age and initial performance status as prognostic factors in patients treated with this drug. VI. Determine whether biological and imaging markers are associated with clinical efficacy of this drug, such as 6-month PFS, in these patients. OUTLINE: This is a multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 11-38 months.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-932b0c350c47c50f3d9c
      requested nct id
      NCT00025233
      primary nct id
      NCT00025233
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      6955ea6d88f2638dea0c76acc97151b275d6a4c31db28ecdc8d9cabd729d6101
      payload sha256
      581a9a8666d21764570806f53f8ddc5c7f27ab193c9debbfbf3120a8c31feccd
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-932b0c350c47c50f3d9c
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00025233
      occurrences
      1. context exact
        mab [<a href="#cit/section_9.13">13</a>]</td> <td>11%; 24% survived progression free for at least 6 months, as seen in <a href="/clinicaltrials/NCT00025233">GOG-0227C</a> (NCT00025233) </td> </tr> <tr> <td>Ifosfamide/cisplatin [<a href="#cit/section_9.14">14</a>,<a href=
        end
        227854
        exact text
        NCT00025233
        start
        227843
      2. context exact
        .13">13</a>]</td> <td>11%; 24% survived progression free for at least 6 months, as seen in <a href="/clinicaltrials/NCT00025233">GOG-0227C</a> (NCT00025233) </td> </tr> <tr> <td>Ifosfamide/cisplatin [<a href="#cit/section_9.14">14</a>,<a href="#cit/section_9.15">15</a>]<
        end
        227882
        exact text
        NCT00025233
        start
        227871
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/54c89187d215055b46.html
      source file sha256
      6955ea6d88f2638dea0c76acc97151b275d6a4c31db28ecdc8d9cabd729d6101
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:36.858766+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      a3232984df74a1d9a0f043dc5a178abeec22b6bc2629401b770fc7d9a7b60dfd
      source title
      Cervical Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 13, 2025
        datetime
        2025-05-13T12:00:00Z
        display
        May 13, 2025

    Preserved source evidence · Not medical advice